Skip to content

Efficacy evaluation of improving cardiopulmonary exercise tolerance of stable coronary heart disease by activating blood circulation and removing blood stasis

A single center, prospective, randomized, blank controlled clinical study to evaluate cardiopulmonary exercise test and exercise tolerance changes in patients with stable coronary heart disease after taking Guanxining tablets

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042591
Enrollment
Unknown
Registered
2021-01-23
Start date
2021-02-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable coronary heart disease

Interventions

Sponsors

Beijing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 years; (2) Meet the diagnostic criteria for stable coronary heart disease, coronary artery stenosis confirmed by coronary angiography or coronary CT angiography is >= 50%, or patients with acute coronary syndrome have stable condition >= 3 months after percutaneous coronary intervention (PCI) (low or moderate risk of exercise rehabilitation); (3) Clinical symptoms of chest tightness or chest pain, or exertional angina pectoris, or old history of myocardial infarction, or clinically diagnosed heart failure (including ejection fraction retention heart failure); (4) Signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with acute myocardial infarction, unstable angina pectoris or uncontrolled arrhythmia in the last 3 months; (2) With severe aortic stenosis, acute aortic dissection, acute myocarditis, pericarditis or aneurysms, severe pulmonary hypertension, acute pulmonary embolism and pulmonary infarction, pulmonary bulla, cardiopulmonary diseases such as emphysema, respiratory failure, or heart failure, cardiac function III level and above); (3) Patients with acute cerebrovascular disease; (4) Poor hypertension control (systolic blood pressure >= 160mmHg or diastolic blood pressure >= 100mmHg); (5) Uncontrolled arrhythmias with clinical symptoms or hemodynamic disturbances; (6) Patients with abnormal liver function (ALT or AST higher than 2 times the upper limit of normal value), abnormal renal function (CR >3mg/ dL or 265.2umol/ L), or with severe primary diseases of liver, kidney, hematopoietic system, acute infectious diseases, electrolyte disturbance, mental illness, or with other diseases are not suitable for the cardiopulmonary exercise test; (7) Women who are pregnant, planning to become pregnant or lactating; (8) Patients who have had major cranial and thoracic and abdominal operations within the last 4 weeks and have bleeding tendency; (9) Participating in other clinical trials within the last 1 month; (10) Allergic to the test drug or its ingredients.

Design outcomes

Primary

MeasureTime frame
Peak O2;

Countries

China

Contacts

Public ContactZhenyu Wang

Beijing Hospital of Traditional Chinese Medicine

wangzhenyu@yeah.com+86 13683080300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026